{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:28:49Z","timestamp":1780410529665,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To date, there are limited published data from randomized trials evaluating the effects of integrase strand transfer inhibitor-based regimens, including dolutegravir-based antiretroviral therapy (ART), on blood pressure (BP) in people with HIV-1 (PWH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This analysis evaluated BP changes from baseline and incident hypertension among ART-naive PWH randomized to dolutegravir-based three-drug ART or alternative comparator ART (cART) across pooled Phase 2\/3 studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this post hoc analysis of Phase 2\/3 SPRING-1, SPRING-2, SINGLE and FLAMINGO clinical trials, BP was assessed at baseline, Week (W) 48 and W96. In PWH without evidence of hypertension at baseline, incident hypertension was defined as a single systolic BP\u200a\u2265\u200a140 mmHg and\/or diastolic BP\u200a\u2265\u200a90 mmHg measured after a 5 min rest, a hypertension adverse event and\/or antihypertensive medication use during follow-up. Baseline factors associated with incident hypertension at W96 were assessed through multivariate analyses. BP changes between dolutegravir and cART were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 2345 randomized participants, 1815 (77%) had no evidence of hypertension at baseline; 927 received dolutegravir-based ART and 888 received cART. Through W96, incident hypertension did not differ between groups [dolutegravir, 23% (n\u200a=\u200a180\/779); cART, 21% (n\u200a=\u200a139\/665); adjusted OR, 1.02; 95% CI, 0.79\u20131.33]; \u223c1% of participants initiated antihypertensive medication through W96 (dolutegravir, n\u200a=\u200a3; cART, n\u200a=\u200a1). At W96, no significant BP changes from baseline were observed (systolic BP, P\u200a=\u200a0.741; diastolic BP, P\u200a=\u200a0.683).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Relative to non-dolutegravir-containing cART, dolutegravir-containing three-drug ART did not show any impact on incident hypertension in ART-naive PWH without evidence of hypertension at baseline through W96.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf212","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T15:30:10Z","timestamp":1753803010000},"page":"2375-2383","source":"Crossref","is-referenced-by-count":2,"title":["Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks"],"prefix":"10.1093","volume":"80","author":[{"given":"Parul","family":"Patel","sequence":"first","affiliation":[{"name":"ViiV Healthcare , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Milinkovic","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grove","sequence":"additional","affiliation":[{"name":"GSK , Brentford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Govan","sequence":"additional","affiliation":[{"name":"GSK , Brentford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McKenna","sequence":"additional","affiliation":[{"name":"GSK , Brentford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Henegar","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona and University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dimondi","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Chow","sequence":"additional","affiliation":[{"name":"GSK , Mississauga, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassrin","family":"Payvandi","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2025090219521982000_dkaf212-B1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"2025090219521982000_dkaf212-B2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025090219521982000_dkaf212-B3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/cid\/ciw223","article-title":"Hypertension among HIV-infected patients in clinical care, 1996\u20132013","volume":"63","author":"Okeke","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025090219521982000_dkaf212-B4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2025090219521982000_dkaf212-B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13643-018-0927-y","article-title":"Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa\u2014a systematic review and meta-analysis","volume":"8","author":"Todowede","year":"2019","journal-title":"Syst Rev"},{"key":"2025090219521982000_dkaf212-B6","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/S2352-3018(22)00400-3","article-title":"Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study","volume":"10","author":"Verheij","year":"2023","journal-title":"Lancet HIV"},{"key":"2025090219521982000_dkaf212-B7","doi-asserted-by":"publisher","first-page":"e15024","DOI":"10.1097\/MD.0000000000015024","article-title":"Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus","volume":"98","author":"Dakum","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025090219521982000_dkaf212-B8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11906-020-01089-3","article-title":"Hypertension and metabolic syndrome in persons with HIV","volume":"22","author":"Masenga","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"2025090219521982000_dkaf212-B9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/hiv.13273","article-title":"Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium","volume":"23","author":"Byonanebye","year":"2022","journal-title":"HIV Med"},{"key":"2025090219521982000_dkaf212-B10","author":"Byonanebye"},{"key":"2025090219521982000_dkaf212-B11","doi-asserted-by":"publisher","first-page":"ofab537","DOI":"10.1093\/ofid\/ofab537","article-title":"Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: a propensity-weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus","volume":"8","author":"Kileel","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025090219521982000_dkaf212-B12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","article-title":"Obesity and weight gain in persons with HIV","volume":"17","author":"Bailin","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025090219521982000_dkaf212-B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2025090219521982000_dkaf212-B14","doi-asserted-by":"crossref","first-page":"2325958221996860","DOI":"10.1177\/2325958221996860","article-title":"Weight gain in incarcerated individuals living with HIV after switching to integrase strand inhibitor-based therapy","volume":"20","author":"Goldberg","year":"2021","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025090219521982000_dkaf212-B15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2025090219521982000_dkaf212-B16","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025090219521982000_dkaf212-B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cca.2016.11.009","article-title":"Fasting insulin, insulin resistance and risk of hypertension in the general population: a meta-analysis","volume":"464","author":"Wang","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2025090219521982000_dkaf212-B18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/HYPERTENSIONAHA.117.07802","article-title":"Oxidative stress, inflammation, and vascular aging in hypertension","volume":"70","author":"Guzik","year":"2017","journal-title":"Hypertension"},{"key":"2025090219521982000_dkaf212-B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025090219521982000_dkaf212-B20","author":"European AIDS Clinical Society"},{"key":"2025090219521982000_dkaf212-B21","author":"Venter"},{"key":"2025090219521982000_dkaf212-B22","author":"Mascolini"},{"key":"2025090219521982000_dkaf212-B23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/cid\/ciad297","article-title":"Incidence of hypertension and blood pressure changes in persons with human immunodeficiency virus at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial","volume":"77","author":"Sempere","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025090219521982000_dkaf212-B24","author":"Patel"},{"key":"2025090219521982000_dkaf212-B25","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48\u2005week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2025090219521982000_dkaf212-B26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48\u2005week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"2025090219521982000_dkaf212-B27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"AIDS"},{"key":"2025090219521982000_dkaf212-B28","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2025090219521982000_dkaf212-B29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"van Lunzen","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2025090219521982000_dkaf212-B30","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2025090219521982000_dkaf212-B31","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/v14112558","article-title":"Real-world effectiveness, tolerability, and safety of dolutegravir\/lamivudine in Korea","volume":"14","author":"Lee","year":"2022","journal-title":"Viruses"},{"key":"2025090219521982000_dkaf212-B32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/hiv.13500","article-title":"Three-year efficacy of switching to dolutegravir plus lamivudine: a real-world study","volume":"24","author":"Palmier","year":"2023","journal-title":"HIV Med"},{"key":"2025090219521982000_dkaf212-B33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/QAD.0000000000003480","article-title":"Real world use of dolutegravir two drug regimens","volume":"37","author":"Bowman","year":"2023","journal-title":"AIDS"},{"key":"2025090219521982000_dkaf212-B34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/ajh\/hpac085","article-title":"Blood pressure and body composition during first year of antiretroviral therapy in people with HIV compared with HIV-uninfected community controls","volume":"35","author":"Kavishe","year":"2022","journal-title":"Am J Hypertens"},{"key":"2025090219521982000_dkaf212-B35","doi-asserted-by":"publisher","first-page":"11196","DOI":"10.3390\/ijerph191811196","article-title":"Risk factors attributable to hypertension among HIV-infected patients on antiretroviral therapy in selected rural districts of the Eastern Cape Province, South Africa","volume":"19","author":"Tsuro","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025090219521982000_dkaf212-B36","volume-title":"Essential Hypertension","author":"Iqbal","year":"2022"},{"key":"2025090219521982000_dkaf212-B37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/MAJ.0000000000000308","article-title":"Racial differences in hypertension: implications for high blood pressure management","volume":"348","author":"Lackland","year":"2014","journal-title":"Am J Med Sci"},{"key":"2025090219521982000_dkaf212-B38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/hiv.12639","article-title":"Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the data collection on adverse events of anti-HIV drugs (DAD) study","volume":"19","author":"Hatleberg","year":"2018","journal-title":"HIV Med"},{"key":"2025090219521982000_dkaf212-B39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.11604\/pamj.2021.39.237.29718","article-title":"Prevalence and correlates of hypertension in HIV-positive adults from the Livingstone Central Hospital, Zambia","volume":"39","author":"Musekwa","year":"2021","journal-title":"Pan Afr Med J"},{"key":"2025090219521982000_dkaf212-B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1570162X18666200131122206","article-title":"Cumulative HIV viremia copy-years and hypertension in people living with HIV","volume":"18","author":"Xu","year":"2020","journal-title":"Curr HIV Res"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2375\/63878467\/dkaf212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2375\/63878467\/dkaf212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:52:24Z","timestamp":1756857144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/9\/2375\/8216997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf212","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,29]]}}}